SRNE Sorrento Therapeutics Inc

Sorrento Issues Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

Sorrento Issues Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

SAN DIEGO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a supplement to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento.

The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation’s removal of the contra-CUSIP on Scilex common stock that was distributed as a dividend to Sorrento’s stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed therein that a dividend confirmation had previously been distributed to such firms by Scilex’s transfer agent and requests that such firms contact Scilex’s transfer agent if they have not received such confirmation. The supplement also reiterates a question related to issues that may arise with respect to the dividend in connection with short positions in Sorrento common stock.

The supplement to the FAQs and related annex are included in this press release and can also be found

SUPPLEMENT TO

FREQUENTLY
ASKED QUESTIONS 

REGARDING THE DIVIDEND OF SCILEX HOLDING COMPANY COMMON STOCK BY

SORRENTO THERAPEUTICS, INC.

This supplement is a supplement to the Frequently Asked Questions Regarding the Dividend of Scilex Holding Company Common Stock by Sorrento Therapeutics, Inc. (Sorrento) that was issued by Sorrento on January 29, 2023 (the FAQ), a copy of which can be found under the “Investors” section of its website at This supplement is being issued to update and supplement the information in the FAQ to notify investors regarding certain matters relating to the dividend and reiterate certain questions and answers from the FAQ. Capitalized terms used in this supplement shall have their respective meetings set forth in the FAQ.

NOTICE OF REMOVAL OF CONTRA-CUSIP BY DTCC

Effective as of February 2, 2023, the Depository Trust and Clearing Corporation has removed the “contra-CUSIP” that it had previously imposed on the Dividend Stock. Any shares of Dividend Stock held by your brokerage firm, bank, dealer or other similar organization for your benefit now bear only Scilex’s CUSIP number, which is 80880W106. If you are entitled to receive Dividend Stock, please contact your brokerage firm, bank, or other similar organization immediately to confirm that the CUSIP number appears on your brokerage statement with respect to your Dividend Stock.

NOTICE TO BROKERAGE FIRMS, BANKS, DEALERS AND OTHER SIMILAR ORGANIZATIONS

If the name of your firm, bank or other similar organization is set forth on Annex B of the FAQ, which Annex B is repeated below for convenience, and your firm, bank or similar organization has not received the Dividend Confirmation that was mailed to your firm, bank or similar organization, please contact Scilex’s transfer agent immediately to obtain a copy of the Dividend Confirmation. Please note that copies of the Dividend Confirmations mailed to the organizations set forth on Annex B are set forth on the Annex B-1. Scilex’s transfer agent’s contact information is as follows:

Continental Stock Transfer & Trust Company

Telephone Number
: 800-509-5586 

Email Address:

Several major brokers have confirmed to Sorrento and Scilex that they are adding the Scilex share positions to the individual brokerage accounts of Sorrento shareholders receiving the Dividend Stock.

SUPPLEMENTAL QUESTION AND ANSWER

Q:If I loaned my shares of Sorrento common stock to short sellers or any other party as of the Record Date, am I still entitled to receive Dividend Stock as of the Payment Date?
A:Only Record Holders as of the Record Date are entitled to receive the Dividend Stock. If you were the Record Holder as of the Record Date and are entitled to receive the Dividend Stock, but have not received the Dividend Stock, you may be entitled to receive Dividend Stock from the short seller or other party who borrowed your shares of Sorrento common stock, whether through the lending programs implemented by your brokerage firm, bank, dealer and other similar organization or otherwise. If you were a Record Holder as of the Record Date and have not received your Dividend Stock, please consult with your financial advisor, broker or other agent immediately to determine how to receive your Dividend

Stock.

Annex B

Broker
List

Broker NameBroker Address Broker NameBroker Address
ABN AMRO CLEARING CHICAGO LLC175 WEST JACKSON BLVD. CHICAGO

IL ILLINOIS 60604 US
Albert Fried & Company LLC45 BROADWAY, 24TH FLOOR

24TH FLOOR NEW YORK NY NEW YORK

10006 US
AMALGAMATED BANK275 7TH AVENUE NEW YORK

NY NEW YORK 10003 US
AMERICAN ENTERPRISE INVESTMENT SERVICES INC.682 AMERIPRISE FINANCIAL CENTER MINNEAPOLIS

MN MINNESOTA 55474 US



Broker NameBroker Address Broker NameBroker Address
APEX CLEARING CORPORATION2 GATEWAY

CENTER 283-299 MARKET ST 16TH FLOOR NEWARK

NJ NEW JERSEY 07102-5005 US
BANK OF AMERICA, NA/GWIM TRUST OPERATIONS901 MAIN STREET

12TH FLOOR DALLAS

TX TEXAS 23113 US
BANK OF NEW YORK MELLON111 SANDERS CREEK PARKWAY 2ND FLOOR

2ND FLOOR EAST SYRACUSE NY NEW YORK 13057 US.
BARCLAYS CAPITAL INC.DTC CUSTODY PARTICIPANT- NY WINDOW -570 WASHINGTON BLVD (ATTN: ROSA HICKS- MILLER OR ROBERT MENDEZ

JERSEY CITY NJ NEW JERSEY

07310 US
BARCLAYS CAPITAL INC.DTC CUSTODY PARTICIPANT- NY WINDOW -570 WASHINGTON BLVD (ATTN: ROSA HICKS-MILLER OR ROBERT MENDEZ JERSEY CITY

NJ NEW JERSEY 07310 US
BMO CAPITAL MARKETS CORP.3 2ND STREET

12TH FLOOR JERSEY CITY NJ NEW JERSEY 07302 US
BMO HARRIS BANK NA/TRUST11270 W PARK PL MILWAUKEE

WI WISCONSIN 53224 US
BMO Nesbitt Burns Inc., Toronto250 YONGE STREET,

7TH FLOOR

7TH FLOOR TORONTO ON ONTARIO M5B 2M8 CA

CANADA
BNP PARIBAS, NEW YORK BRANCH/BNP PARIBAS PRIME

BROKERAGE CUSTODIAN
100 WEST 33RD STREET

3RD FLOOR NEW YORK NY NEW YORK

10001
BNP PARIBAS, NEW YORK BRANCH/BNP PARIBAS PRIME

BROKERAGE CUSTODIAN
100 WEST 33RD STREET

3RD FLOOR NEW YORK NY NEW YORK

10001
BNY MELLONPO BOX 392002

500 ROSS STREET PITTSBURGH

PA

PENNSYLVANIA 15262 US
BNY MELLON/WEALTH MANAGEMENT1 FREEDOM VALLEY DRIVE

OAKS

PA PENNSYLVANIA 19456 US
BNYMELLON111 SANDERS CREEK PARKWAY 2ND FLOOR

2ND FLOOR EAST SYRACUSE
BNYMELLON/RE BARCLAYS CAPITAL SECURITIES LTD.ONE WALL STREET NEW YORK

NY NEW YORK 10286



Broker NameBroker Address Broker NameBroker Address
 NY NEW YORK 13057 US  
BNYMELLON/RE CACEIS BANK LUXEMBOURG500 Grant St.

BNY Mellon Center PITTSBURGH

PA PENNSYLVANIA

15258
BNYMELLON/RE CACEIS BANK, NETHERLANDS111 SANDERS CREEK PARKWAY

EAST SYRACUSE NY NEW YORK 13057
BNYMELLON/RE CHARLES STANLEY AND COMPANY, LIMITED111 SANDERS CREEK PARKWAY 2ND FLOOR

2ND FLOOR EAST SYRACUSE NY NEW YORK

13057 US
BNYMELLON/RE ETF - ISHARES DTC/NSCC111 SANDERS CREEK PARKWAY

EAST SYRACUSE NY NEW YORK 13057
BNYMELLON/RE WINTERFLOOD SECURITIES LTD500 Grant St.

BNY Mellon Center PITTSBURGH

PA PENNSYLVANIA 15258
BOFA4804 Deer Lake Drive East

FL9-803-04-04- 4th

floor JACKSONVILLE FL FLORIDA

32246 US
BOFA4804 Deer Lake Drive East

FL9-803-04-04- 4th

floor JACKSONVILLE FL FLORIDA

32246 US
BOFA SECURITIES INC4804 Deer Lake Drive East

FL9-803-04-04- 4th

floor JACKSONVILLE FL FLORIDA

32246 US
BROWN BROTHERS HARRIMAN & CO.140 BROADWAY ATTN: CORPORATE ACTIONS VAULT NEW YORK

NY NEW YORK 10005 US
BROWN BROTHERS HARRIMAN & CO./ETF140 BROADWAY NEW YORK

NY NEW YORK 10005
CALDWELL SECURITIES LTD./CDS**55 UNIVERSITY AVENUE

SUITE 340 TORONTO ON ONTARIO

M5J 2H7 CANADA
CANACCORD GENUITY CORP.609 GRANVILLE ST VANCOUVER

BC BRITISH COLUMBIA

V7Y 1H2 CA CANADA
CANTOR, FITZGERALD & CO.135 E 57TH ST 5TH FL

NEW YORK

NY NEW YORK 10041 US
CDS CLEARING AND DEPOSITORY SERVICES INC.100 ADELAIDE STREET WEST TORONTO

ON ONTARIO

M5H 1S3 CA CANADA
CETERA INVESTMENT SERVICES LLC400 FIRST STREET

SOUTH, SUITE 300

SUITE 300 ST. CLOUD
CHARLES SCHWAB & CO., INC.211 MAIN STREET SAN FRANCISCO CA CALIFORNIA

94105 US



Broker NameBroker Address Broker NameBroker Address
 MN MINNESOTA 56302-0283 US  
CI INVESTMENT SERVICES INC.199 BAY STREET

SUITE 2600 TORONTO ON ONTARIO M5L 1E2 CA

CANADA
CIBC WORLD MARKETS INC./CDS**161 BAY STREET 10 FL

TORONTO ON ONTARIO

M5J 2S8 CA CANADA
CITIBANK, N.A./ETF3800 CITIGROUP CENTER

B2/2 TAMPA

FL FLORIDA 33610
CITIBANK, NATIONAL ASSOCIATION3800 CITIBANK CENTER TAMPA BLDG.B FIRST FLOOR ZONE 8 TAMPA

FL FLORIDA 33610-9122 US
CITIGROUP GLOBAL MARKETS, INC.580 CROSSPOINT PARKWAY GETZVILLE

NY NEW YORK 14068 US
CLEAR STREET LLC4 World Trade Center, 45th Floor

150 Greenwich Street NEW YORK

NY NEW YORK 10007
CLEARSTREET IO55 BROADWAY

(SUITE 2102) CORPORATE ACTIONS NEW YORK

NEW YORK 10006 US
COMMERCE BANK922 WALNUT STREET MAIL STOP TBTS-2 KANSAS CITY

MO MISSOURI 64106 US
COR CLEARING LLC9300 UNDERWOOD AVE

SUITE 400 OMAHA

NE NEBRASKA 68114 US
Credential Securities Inc.800-1111 WEST GEORGIA STREET VANCOUVER

BC BRITISH COLUMBIA

V6E 4T6 CA CANADA
CREST INTERNATIONAL NOMINEES LIMITED33 CANNON STREET LONDON EC4M 5SB GB

UNITED KINGDO
CURVATURE SECURITIES, LLC39 MAIN STREET CHATHAM

NJ NEW JERSEY 07928 US
D.A. DAVIDSON & CO.8 3RD STREET NORTH GREAT FALLS MT MONTANA

59401 US
DEPOSITO CENTRAL DE VALORES S.A., DEPOSITO DE

VALORES
AVENIDA APOQUINDO # 4001

FLOOR 12, C.P.

7550162, SANTIAGO CL CHILE



Broker NameBroker Address Broker NameBroker Address
DESJARDINS SECURITIES INC.1253 McGill College 10TH FLOOR MONTREAL QUEBEC

H3B 2Y5 CA CANADA
DEUTSCHE BANK AG NY/US CUSTODY1251 Avenue Of The Americas

NEW YORK NY NEW YORK 10020
DEUTSCHE BANK SECURITIES INC.60 WALL STREET

9TH FLOOR NEW YORK NY NEW YORK 10005 US
DRIVEWEALTH, LLC15 EXCHANGE PLACE

10TH FLOOR JERSEY CITY

NEW JERSEY 07302
E*TRADE CLEARING LLCHARBORSIDE FINANCIAL CENTER

501 PLAZA 11 JERSEY CITY

NJ NEW JERSEY 07311 US
EDWARD D. JONES & CO., L.P.12555 MANCHESTER ROAD

ST. LOUIS

MO MISSOURI 63131-3729 US
EDWARD D. JONES & CO., L.P.201 PROGRESS PARKWAY MARYLAND HEIGHTS

MO MISSOURI 63043 US
FIDELITY CLEARING CANADA

ULC/CDS**
483 BAY ST. SOUTH TOWER TORONTO

ON ONTARIO M5G2N7 CA CANADA
FIFTH THIRD BANK5001 KINGSLEY DRIVE

MAIL DROP 1MOB28 CINCINNATI

OH OHIO 45227 US
FOLIO INVESTMENTS, INC.8180 GREENSBORO DRIVE

8TH FLOOR MCLEAN

VA VIRGINIA 22102 US
FUTU CLEARING INC.12750 Merit Drive

SUITE 475 DALLAS TX TEXAS 75251
GMP SECURITIES L.P.145 KING STREET

WEST, SUITE 300 11TH FLOOR TORONTO

ON ONTARIO

MJ5 1J8 CA CANADA
GOLDMAN, SACHS & CO. LLC222 SOUTH MAIN STREET

Attn: Mandatory Corporate Actions SALT LAKE CITY UT UTAH

84101 US
HAYWOOD SECURITIES INC./CDS**200 BURRARD ST WATERFRONT CENTRE SUITE 700 VANCOUVER

BC BRITISH COLUMBIA

V6C 3L6 CANADA
HILLTOP SECURITIES INC.1201 ELM ST.

35TH FLOOR DALLAS

TX TEXAS

75270 US
HRT FINANCIAL LLC150 GREENWICH STREET (ATTN: SETTLEMENT) FOUR WORLD TRADE

CENTER



Broker NameBroker Address Broker NameBroker Address
   57TH FLOOR NEW YORK NY NEW YORK

10007 US
HSBC BANK USA, NA/HSBC CUSTODY & CLEARING SERVICES FOR

STOCK LOAN
452 FIFTH AVENUE ATTN: HBUS CCS SETTS

NEW YORK NY NEW YORK

10018 US
HSBC BANK USA, NATIONAL ASSOCIATION452 FIFTH AVENUE ATTN: HBUS CCS SETTS

NEW YORK NEW YORK

10018 US
INTERACTIVE BROKERS LLC2 PICKWICK PLAZA

2ND FLOOR GREENWICH

CT CONNECTICUT

06830 US
J.P. MORGAN CHASE BANK NA/FBO BLACKROCK CTF1111 POLARIS PARKWAY COLUMBUS OH OHIO

43240
J.P. MORGAN CLEARING CORP.FOUR CHASE METROTECH CENTER

3RD FLOOR BROOKLYN NY NEW YORK

11201 US
JANNEY MONTGOMERY SCOTT LLC1717 ARCH STREET

17TH FLOOR PHILADELPHIA

PA PENNSYLVANIA 19103 US
JEFFERIES LLC101 HUDSON

STREET, 11th Floor NEW JERSEY

NJ NEW JERSEY 07302 US
JPMORGAN CHASE BANK, NATIONAL ASSOCIATIONFOUR CHASE METROTECH CENTER

3RD FLOOR BROOKLYN NY NEW YORK

11201 US
JPMORGAN CHASE BANK/EUROCLEAR BANKFOUR CHASE METROTECH CENTER

3RD FLOOR BROOKLYN NY NEW YORK

11245 US
JPMORGAN CHASE BANK/IAFOUR CHASE METROTECH CENTER

3RD FLOOR BROOKLYN NY NEW YORK

11201 US
KEYBANK NATIONAL ASSOCIATION4900 TIEDEMAN RD BROOKLYN

OH OHIO 44144 US
LAURENTIAN BANK SECURITIES INC.1981 MCGILL COLLEGE AVE. SUITE 100 MONTREAL QUEBEC

H3A 3K3 CA CANADA
LPL FINANCIAL LLC4707 EXECUTIVE DRIVE

SAN DIEGO

CA CALIFORNIA 92121 US
MANUFACTURERS AND TRADERS TRUST COMPANYONE M&T PLAZA TRUST OPS 8TH FLOOR BUFFALO

NY NEW YORK 14203 US



Broker NameBroker Address Broker NameBroker Address
MANULIFE SECURITIES INCORPORATED1235 NORTH SERVICE ROAD WEST OAKVILLE

ON ONTARIO

L6M 2W2 CA CANADA
MARSCO INVESTMENT CORPORATION101 EISENHOWER PARKWAY ROSELAND

NJ NEW JERSEY 07068 US
MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED4804 Deer Lake Drive East

FL9-803-04-04- 4th

floor JACKSONVILLE FL FLORIDA

32246 US
MIRAE ASSET SECURITIES (USA) INC./STOCK LOAN CONDUIT ACCOUNT810 SEVENTH AVE

37TH FLOOR NEW YORK

NY NEW YORK 10019
MIRAE ASSET SECURITIES (USA), INC.810 SEVENTH AVE

37TH FLOOR NEW YORK NY NEW YORK 10019
MITSUBISHI UFJ TRUST & BANKING CORPORATION, NEW YORK BRANCH280 PARK AVE

39TH FL-WEST BLDG NEW YORK

NY NEW YORK 10017
Morgan Stanley1300 THAMES STREET

THAMES STREET WHARF BALTIMORE

MD MARYLAND 21231 US
MORGAN STANLEY & CO. LLC1300 THAMES ST. BALTIMORE

MD MARYLAND
MORGAN STANLEY SMITH BARNEY LLC1 NEW YORK PLAZA

39TH FLOOR NEW YORK

NY NEW YORK 10004 US
MURIEL SIEBERT & CO., INC.77 SUMMER STREET

3RD FLOOR BOSTON MA

MASSACHUSETTS 02210 US
NATIONAL FINANCIAL SERVICES LLC499 WASHINGTON BOULEVARD

5TH FLOOR JERSEY CITY NJ NEW JERSEY

07310 US
NBCN INC.1010 rue De La Gauchetière Mezzanine 100 MONTREAL QUEBEC

H3B 5J2 CA CANADA
NOMURA INTERNATIONAL TRUST COMPANY309 WEST 49TH STREET

10TH FLOOR NEW YORK NY NEW YORK

10019 US
ODLUM BROWN LIMITED250 HOWE STREET

SUITE 1100 VANCOUVER BC BRITISH COLUMBIA

V6C 3R8 CA CANADA
OPPENHEIMER & CO. INC.85 BROAD STREET NEW YORK

NY NEW YORK 10004 US
PERSHING LLC1 PERSHING PLAZA JERSEY CITY

NJ NEW JERSEY 07399 US



Broker NameBroker Address Broker NameBroker Address
PHILLIP CAPITAL INC.141 W. JACKSON

BLVD. SUITE 3050 CHICAGO

IL ILLINOIS 60604 US
PI FINANCIAL CORP.666 BURRARD ST

SUITE 1900 VANCOUVER BC BRITISH COLUMBIA

V6C 3N1 CA CANADA
PNC BANK, NATIONAL ASSOCIATION4100 W 150TH STREET

ASSET MOVEMENT TEAM 3RD FL, LOCATOR B7- YB17-03-03 CLEVELAND

OH OHIO 44135 US
PRINCIPAL BANK711 HIGH STREET DES MOINES

IA IOWA 50392
QUESTRADE INC./CDS**5650 YONGE ST.,

Suite 1700 TORONTO ON ONTARIO M2M 4G3 CA

CANADA
Raymond James & Associates, Inc.880 CARILLON PKWY ST. PETERSBURG

FL FLORIDA 33733-2749 US
RAYMOND JAMES LTD.925 WEST GEORGIA STREET SUITE 2200 VANCOUVER



BC BRITISH COLUMBIA V6C 3L2 CA

CANADA
RBC CAPITAL MARKETS, LLC60 SOUTH 6TH ST. MINNEAPOLIS MN MINNESOTA 55402 US
RBC DOMINION SECURITIES INC21 COMMERCE COURT SOUTH 2ND FLOOR TORONTO

ON ONTARIO

M5L 1A7 CANADA
RELIANCE TRUST COMPANY1100 ABERNATHY RD.

500 NORTHPARK

SUITE 400 ATLANTA GA GEORGIA

30113 US
RELIANCE TRUST COMPANY4900 W. BROWN DEER RD MILWAUKEE WI WISCONSIN 53223 USROBERT W. BAIRD & CO. INCORPORATED777 E WISCONSIN AVE

9TH FLOOR MILWAUKEE WI WISCONSIN

53202 US
ROBINHOOD SECURITIES, LLC500 COLONIAL CENTER PARKWAY SUITE 100 LAKE MARY FL FLORIDA

32746 US
SAFRA SECURITIES LLC546 5TH AVENUE NEW YORK

NY NEW YORK 10036 US



Broker NameBroker Address Broker NameBroker Address
SCOTIA CAPITAL (USA) INC.150 KING STREET W

5TH FLOOR TORONTO ON ONTARIO M5H 1J9 CA

CANADA
SEI PRIVATE TRUST COMPANY1 FREEDOM VALLEY DRIVE

OAKS

PA PENNSYLVANIA 19456 US
SEI PRIVATE TRUST COMPANY1 FREEDOM VALLEY DRIVE OAKS

PA PENNSYLVANIA

19456 US
SG AMERICAS SECURITIES, LLC480 WASHINGTON BLVD.

20TH FLOOR JERSEY CITY NJ NEW JERSEY

07310 US
SSB - BLACKROCK INSTITUTIONAL TRUST50 California Street San Francisco

CA CALIFORNIA 94163
SSB - TRUST CUSTODY30 ADELAIDE ST EAST

SUITE 800 TORONTO ON ONTARIO M5C 3G6 CA

CANADA
SSB&T CO/CLIENT CUSTODY SERVICES1776 HERITAGE DRIVE

NORTH QUINCY MA

MASSACHUSETTS 02171
STATE STREET BANK & TRUST CO16 WALL STREET

5TH FLOOR NEW YORK

NY NEW YORK 10005 US
STATE STREET BANK & TRUST COMPANY / ISHARES EUROPE1776 HERITAGE DRIVE

NORTH QUINCY MA MASSACHUSETTS

02171
STATE STREET BANK & TRUST/STATE STREET TOTALETF1776 Heritage Drive NORTH QUINCY MA MASSACHUSETTS 02717
STATE STREET BANK AND TRUST COMPANY30 ADELAIDE ST EAST

SUITE 800 TORONTO ON ONTARIO

M5C 3G6 CA CANADA
STIFEL, NICOLAUS & COMPANY, INCORPORATED501 N BROADWAY ST. LOUIS

MO MISSOURI 63102 US
STONEX FINANCIAL INC.2 PERIMETER PARK SOUTH SUITE 100 W BIRMINGHAM AL ALABAMA

35243 US
TD AMERITRADE CLEARING, INC.200 S 108TH AVE OMAHA

NE NEBRASKA 68154 US
TD WATERHOUSE CANADA INC ATTN: MANDATORY77 BLOOR STREET WEST

3RD FLOOR TORONTO

ON ONTARIO
TEXAS TREASURY SAFEKEEPING TRUST COMPANY208 E 10TH ST AUSTIN

TX TEXAS 78701 US



Broker NameBroker Address Broker NameBroker Address
CORPORATE ACTIONSM5S 1M2 CA CANADA  
THE BANK OF NEW YORK MELLON500 GRANT STREET

27TH FLOOR PITTSBURGH PA

PENNSYLVANIA 15258 US
THE HUNTINGTON NATIONAL BANK7 EASTON OVAL EA4E62 COLUMBUS

OH OHIO 43209 US
THE NORTHERN TRUST COMPANY333 South Wabash Ave, 32nd Floor Attn: Trade Securities Processing CHICAGO

IL ILLINOIS 60603 US
TRADESTATION SECURITIES, INC.120 RIVERSIDE PLAZA

SUITE 1650 CHICAGO IL ILLINOIS 60606 US
U.S. BANCORP INVESTMENTS, INC.60 LIVINGSTON AVE

EP-MN-WN1B ST. PAUL

MN MINNESOTA 55107-1419 US
U.S. BANK N.A./ETF1555 N RIVER CENTER DRIVE MILWAUKEE WI WISCONSIN 53212
U.S. BANK NATIONAL ASSOCIATION1555 NORTH RIVERCENTER DRIVE, SUITE 302

SUITE 302 MILWAUKEE

WI WISCONSIN 53212 US
UBS AG480 WASHINGTON BLVD.

12TH FLOOR JERSEY CITY NJ NEW JERSEY 07310 US
UBS FINANCIAL SERVICES INC.1000 HARBOR BOULEVARD WEEHAWKEN NJ NEW JERSEY

07086 US
UBS SECURITIES LLC677 WASHINGTON BLVD

STAMFORD

CT CONNECTICUT 06901 US



Broker NameBroker Address Broker NameBroker Address
UMB BANK, NATIONAL ASSOCIATION928 GRAND BLVD KANSAS CITY MO MISSOURI 64106 USVANGUARD MARKETING CORPORATION100 VANGUARD BLVD MALVERN

PA PENNSYLVANIA 19355 US
VELOCITY CLEARING, LLC1301 Route 36

Suite 109 (Attn: Chris Felicetti)

HAZLET

NEW JERSEY 7730 US
VELOX CLEARING LLC2400 E. KATELLA AVENUE

SUITE 725A ANAHEIM

CA CALIFORNIA 92806 US
VIRTU AMERICAS LLCONE LIBERTY PLAZA, 165 BROADWAY 5TH FLOOR NEW YORK NY NEW YORK

10006 US
VISION FINANCIAL MARKETS LLC4 HIGH RIDGE PARK SUITE 100 STAMFORD

CT CONNECTICUT 06905 US
WEDBUSH SECURITIES INC1000 WILSHIRE BLVD

8TH FLOOR LOS ANGELES

CA CALIFORNIA

90017 US
WEDBUSH SECURITIES INC.1000 WILSHIRE BLVD.

LOS ANGELES CA CALIFORNIA 90017 US
WELLS FARGO BANK, N.A./SIG733 MARQUETTE AVE 4TH FLOOR MAC N9306-04D MINNEAPOLIS

MN MINNESOTA 55402 US
WELLS FARGO CLEARING SERVICES LLC1 NORTH JEFFERSON MAIL CODE: H0006- 094

ST. LOUIS

MO MISSOURI 63103 US
WELLS FARGO SECURITIES, LLC1525 WEST W T HARRIS BLVD CHARLOTTE NC NORTH CAROLINA

28262 US
WILSON-DAVIS & CO., INC.236 SOUTH MAIN STREET

SALT LAKE CITY UT UTAH

84101 US

About Sorrento Therapeutics, Inc.

Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as Abivertinib, next-generation tyrosine kinase inhibitors (“TKIs”), fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including STI-1558, COVI-MSC™; and diagnostic test solutions, including COVIMARK™.

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a TRPV1 agonist, non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. Positive final results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. ZTlido® was approved by the FDA on February 28, 2018.

For more information visit

Media and Investor Relations

Contact: Brian Cooley

Email:

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVI-MSC™, COVIMARK™, Ovydso™ and Fujovee™ are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA™ (SP-102) is a trademark of Semnur Pharmaceuticals, Inc. A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc. All other trademarks are the property of their respective owners.

©2023 Sorrento Therapeutics, Inc. All Rights Reserved.

A PDF accompanying this release is available at 



EN
02/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sorrento Therapeutics Inc

 PRESS RELEASE

Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondar...

Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild or moderate COVID-19 patients were enrolled and treated with OVYDSO™ (Olgotrelvir) or placebo. The primary endpoint was time to sustained recovery of 11 COVID-19 related symptoms and the key secondary endpoint was the viral RNA copy load reduction.Ovydso significantly shortened...

 PRESS RELEASE

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Resul...

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients All study objectives were met, demonstrating safety across dose groups and confirming efficacy and durability at the selected doses against placebo (lidocaine) and active control (steroid).All RTX doses (7.5 to 20 µg) were well-tolerated, with few severe or serious adverse events (AEs). The majority of reported AEs related to pain post-administration and resolved within hours following treatment. Ver...

 PRESS RELEASE

Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests...

Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter 11 case, it has posted a “Frequently Asked Questions” (FAQ) document in response to a number of requests from parties who hold short interests in restricted stock ...

 PRESS RELEASE

Sorrento Announces Positive Phase IIa Study Results of Abivertinib for...

Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study Abivertinib is a novel Bruton’s tyrosine kinase (BTK) inhibitor that irreversibly targets BTK. BTK inhibitors are a large category in cancer treatment, with multiple indications and generating over $10.6 billion per year revenue in 2022.In this phase IIa study conducted in China, a total of 27 R/R MZL patients treated with Abivertinib were assessed and the overall response rate (ORR) was 59.3 % (16/27 patient...

 PRESS RELEASE

Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial wi...

Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19 The Phase 3 study of Ovydso was initiated in China in February 2023 and enrolled and dosed 1,200 COVID-19 patients (1:1, active:placebo) at 25 sites in China.During the trial, Ovydso has maintained an excellent safety profile with no Grade 3 toxicities reported.We anticipate top line data in the third quarter of this year.If the trial meets its endpoints, we have agreements with the China Health Authority ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch